跳到正文
BiotechTV - News(podcasters.spotify.com)· BiotechTV·· 5 天前品質評分58

Jefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA

Jefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA

重點導讀

He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.

AI 伴隨問答

自備 Key 深度分析

針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:

Podcast 專家音訊節目

收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情

正文

He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.

來源: BiotechTV - News (podcasters.spotify.com)
開啟原文

讀者討論

理性交流 · 即時討論